AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35574717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 35541826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 30
Study 35541826 — intervention group
Group type: COMPARATOR
Intervention: Volume Control Ventilation (VCV)
Number of subjects: 30
Study 32176703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, diethylcarbamazine, and albendazole (IDA)
Number of subjects: 3612
Study 32176703 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine and albendazole (DA)
Number of subjects: 3612
Study 32176703 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA
Number of subjects: 3612
Study 32176703 — intervention group
Group type: COMPARATOR
Intervention: DA
Number of subjects: 3612
Study 35157170 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative framing (70% likely to occur)
Number of subjects: 174
Study 35157170 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing (30% unlikely to occur)
Number of subjects: 174
Study 35157170 — intervention group
Group type: COMPARATOR
Intervention: Control (no-headache instruction)
Number of subjects: 174
Study 34349841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine-cisplatin (OV-CDDP) - 60–80 mg/m2 OV days 1 and 8 with 80 mg/m2 CDDP day 1
Number of subjects: 114
Study 34349841 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin (GEM-CDDP) - 1250 mg/m2 GEM days 1 and 8 with 75 mg/m2 CDDP day 1
Number of subjects: 114
Study 35546725 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM titanium abutments bonded to titanium bases
Number of subjects: 24
Study 35546725 — intervention group
Group type: COMPARATOR
Intervention: One-piece CAD/CAM titanium abutments
Number of subjects: 24
Study 34231375 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (250 mEq sodium/day)
Number of subjects: 9
Study 34231375 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (50 mEq sodium/day)
Number of subjects: 9
Study 35384398 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg generic pazopanib tablet
Number of subjects: 32
Study 35384398 — intervention group
Group type: COMPARATOR
Intervention: 200-mg branded pazopanib tablet
Number of subjects: 32
Study 35468807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontargeted HCV screening
Number of subjects: 125000
Study 35468807 — intervention group
Group type: COMPARATOR
Intervention: Targeted HCV screening
Number of subjects: 125000
Study 32682457 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS‐118 (S‐1 plus leucovorin) plus oxaliplatin
Number of subjects: 711
Study 32682457 — intervention group
Group type: COMPARATOR
Intervention: S‐1 plus cisplatin
Number of subjects: 711
Study 32682457 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS‐118 plus oxaliplatin
Number of subjects: 711
Study 33288325 — intervention group
Group type: COMPARATOR
Intervention: Non-prep (NP) veneers
Number of subjects: 64
Study 33288325 — intervention group
Group type: COMPARATOR
Intervention: Minimal-invasive (MI) veneers
Number of subjects: 64
Study 33288325 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-invasive (SI) veneers
Number of subjects: 64
Study 33288325 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive (I) veneers
Number of subjects: 64
Study 33288325 — intervention group
Group type: EXPERIMENTAL
Intervention: Veneer-composite interface
Number of subjects: 64
Study 33288325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-composite interface
Number of subjects: 64
Study 33034942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PRP (platelet-rich plasma)
Number of subjects: 50
Study 33034942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide
Number of subjects: 50
Study 33034942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralesional normal saline)
Number of subjects: 50
Study 33034942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PRP
Number of subjects: 50
Study 35871933 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin
Number of subjects: 150
Study 35871933 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron
Number of subjects: 150
Study 35871933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 34342293 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (CNN) for recognizing AG
Number of subjects: 2741
Study 34342293 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (CNN) for recognizing GIM
Number of subjects: 2741
Study 32737973 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS‐supported multimodal balance training
Number of subjects: 154
Study 32737973 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular multimodal balance training
Number of subjects: 154
Study 32737973 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (educational program)
Number of subjects: 154
Study 35436167 — intervention group
Group type: EXPERIMENTAL
Intervention: Why improve my hearing? Telecare Tool
Number of subjects: 57
Study 35436167 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 57
Study 32930848 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg anthocyanins daily for 12 weeks
Number of subjects: 160
Study 32930848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 35138410 — intervention group
Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty (TSA) followed by usual care
Number of subjects: 102
Study 35138410 — intervention group
Group type: COMPARATOR
Intervention: 12-week exercise program (exercise only)
Number of subjects: 102
Study 35782094 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (n = 49)
Number of subjects: 148
Study 35782094 — intervention group
Group type: COMPARATOR
Intervention: No-choice group (n = 49)
Number of subjects: 148
Study 33023671 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma infusion (two bags of 238-337 ml each on day 1 and day 2)
Number of subjects: 174
Study 33023671 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no convalescent plasma)
Number of subjects: 174
Study 33023671 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma infusion
Number of subjects: 174
Study 33023671 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 174
Study 34001840 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises on stable support surfaces
Number of subjects: 84
Study 34001840 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises on unstable support surfaces
Number of subjects: 84
Study 34001840 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 84
Study 33607790 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 120
Study 33607790 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 33607790 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment only)
Number of subjects: 120
Study 32729819 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of memantine 10-mg tablet under fasting condition
Number of subjects: 20
Study 32729819 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of memantine 10-mg tablet under fed condition
Number of subjects: 20
Study 32729819 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Ebixa 10-mg tablet)
Number of subjects: 20
Study 36181632 — intervention group
Group type: EXPERIMENTAL
Intervention: VOM ethanol infusion
Number of subjects: 129
Study 34601833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency group (size 10 K-file carried 01mm beyond working length)
Number of subjects: 240
Study 34601833 — intervention group
Group type: COMPARATOR
Intervention: Non-patency group (file carried till working length)
Number of subjects: 240
Study 35642688 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling based on the GATHER model
Number of subjects: 80
Study 35642688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 33704435 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients (received at least one dose of mRNA COVID-19 vaccine)
Number of subjects: 39156
Study 33704435 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated patients (did not receive vaccine)
Number of subjects: 39156
Study 33704435 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients >10 days after 1st dose
Number of subjects: 39156
Study 33704435 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients >0 days after 2nd dose
Number of subjects: 39156
Study 32043961 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device (WHOOP, Inc.) providing feedback regarding sleep information for 1 week
Number of subjects: 32
Study 32043961 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device (WHOOP, Inc.)
Number of subjects: 32
Study 33780297 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA intervention (n = 28)
Number of subjects: 61
Study 33982936 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction assay (TissueCypher)
Number of subjects: 155
Study 36078648 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Pilates intervention (PE group)
Number of subjects: 16
Study 36078648 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (CON)
Number of subjects: 16
Study 33599056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training sessions on executive function (8 sessions)
Number of subjects: 61
Study 33599056 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological training)
Number of subjects: 61
Study 33205064 — intervention group
Group type: EXPERIMENTAL
Intervention: AKR-001 (Fc-FGF21 fusion protein) at 70 mg QW
Number of subjects: 0
Study 33205064 — intervention group
Group type: EXPERIMENTAL
Intervention: AKR-001 (Fc-FGF21 fusion protein)
Number of subjects: 0
Study 616389359 — intervention group
Group type: EXPERIMENTAL
Intervention: Meticulous dissection by specially preservation of supraclavicular nerves during open reduction and internal fixation (ORIF)
Number of subjects: 37
Study 616389359 — intervention group
Group type: COMPARATOR
Intervention: Conventional ORIF
Number of subjects: 37
Study 34391872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (maximum dose 2,000 mg/d)
Number of subjects: 51
Study 34391872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 34376438 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum (TQL) block with 0.375% ropivacaine 20 mL on each side
Number of subjects: 0
Study 34376438 — intervention group
Group type: COMPARATOR
Intervention: Oblique subcostal transversus abdominis plane (OSTAP) block with 0.375% ropivacaine 20 mL on each side
Number of subjects: 0
Study 34376438 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum (TQL) block
Number of subjects: 0
Study 35484009 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal rotation taping
Number of subjects: 15
Study 35484009 — intervention group
Group type: EXPERIMENTAL
Intervention: External rotation taping
Number of subjects: 15
Study 35484009 — intervention group
Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study 32066598 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mild hypercapnia (TMH) with PaCO2 45-55 mm Hg
Number of subjects: 40
Study 32066598 — intervention group
Group type: COMPARATOR
Intervention: Targeted normocapnia (TN) with PaCO2 35-40 mm Hg
Number of subjects: 40
Study 34853883 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal calcium intake during pregnancy
Number of subjects: 103
Study 34853883 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal bone resorption (measured by urinary excretion of cross-linked N-telopeptides) during pregnancy
Number of subjects: 103
Study 34853883 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring body mass index
Number of subjects: 103
Study 34853883 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring sex (boys vs girls)
Number of subjects: 103
Study 33966763 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven message variations
Number of subjects: 2607
Study 35531319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia with tramadol
Number of subjects: 200
Study 35531319 — intervention group
Group type: COMPARATOR
Intervention: Control group (Intravenous analgesia with sufentanil)
Number of subjects: 200
Study 32466016 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1 antitrypsin (A1AT)
Number of subjects: 8
Study 32466016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 35869955 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 78
Study 35869955 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release dinoprostone vaginal insert
Number of subjects: 78
Study 34325645 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation
Number of subjects: 90
Study 34325645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35161508 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based dual-task (DT) balance exercise program
Number of subjects: 20
Study 35161508 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 20
Study 34562728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training plus treatment as usual
Number of subjects: 46
Study 34562728 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 46
Study 34580638 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 65
Study 34580638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 65
Study 34580638 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Number of subjects: 65
Study 34580638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 34580638 — intervention group
Group type: COMPARATOR
Intervention: Exenatide vs Placebo
Number of subjects: 65
Study 34580638 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine vs Placebo
Number of subjects: 65
Study 34580638 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine vs Exenatide
Number of subjects: 65
Study 33024061 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Vacuum-Assisted Closure (EVAC)
Number of subjects: 39
Study 33024061 — intervention group
Group type: COMPARATOR
Intervention: Self-Expandable Metallic Stent (SEMS)
Number of subjects: 39
Study 35018648 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion (TCI) with effect compartment concentration set to 3 μg/ml
Number of subjects: 175
Study 34189335 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS) targeting the ventral capsule/ventral striatum (VC/VS) region for three months
Number of subjects: 27
Study 34189335 — intervention group
Group type: COMPARATOR
Intervention: Sham deep brain stimulation
Number of subjects: 27
Study 35422002 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop oxygen control
Number of subjects: 45
Study 35422002 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 45
Study 34234368 — intervention group
Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan (an online goal-setting patient decision aid)
Number of subjects: 17
Study 34234368 — intervention group
Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan
Number of subjects: 17
Study 35254967 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD + AMT
Number of subjects: 21
Study 35254967 — intervention group
Group type: COMPARATOR
Intervention: MAD
Number of subjects: 21
Study 35254967 — intervention group
Group type: COMPARATOR
Intervention: AMT alone
Number of subjects: 21
Study 34081773 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tool PREPAREforYourCare.org (PREPARE)
Number of subjects: 0
Study 32848379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol (5/5 μg and 2.5/5 μg)
Number of subjects: 3100
Study 32848379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol (5/5 μg)
Number of subjects: 3100
Study 32848379 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (5 μg and 2.5 μg) and Olodaterol (5 μg)
Number of subjects: 3100
Study 36356989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 50 mg/emtricitabine (FTC) 200 mg/tenofovir alafenamide (TAF) 25 mg (Biktarvy) taken two times per day
Number of subjects: 120
Study 36356989 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir-based regimen (standard of care)
Number of subjects: 120
Study 33011649 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 179
Study 33011649 — intervention group
Group type: COMPARATOR
Intervention: Single-Disorder Protocols (SDPs)
Number of subjects: 179
Study 35854230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - personalized diet and exercise recommendations, pedometer device for monitoring physical activity.
Number of subjects: 300
Study 35854230 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - baseline general advice and materials for patients undergoing RT.
Number of subjects: 300
Study 34544618 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 = 0.95 (group TH)
Number of subjects: 23
Study 34544618 — intervention group
Group type: COMPARATOR
Intervention: FIO2 = 0.65 (group TL)
Number of subjects: 23
Study 33345866 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL liposomal bupivacaine
Number of subjects: 120
Study 33345866 — intervention group
Group type: COMPARATOR
Intervention: 20-mL 0.25% plain bupivacaine
Number of subjects: 120
Study 35243855 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up protocol (recombinant FSH 75IU sc/day, increasing to 150IU if no response after 7 days)
Number of subjects: 145
Study 35243855 — intervention group
Group type: COMPARATOR
Intervention: Step-down protocol (recombinant FSH 150IU sc/day, decreasing to 75IU after 5 days)
Number of subjects: 145
Study 35243855 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up protocol
Number of subjects: 145
Study 35243855 — intervention group
Group type: COMPARATOR
Intervention: Step-down protocol
Number of subjects: 145
Study 32300774 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation
Number of subjects: 996576
Study 35798016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg orally once daily plus atezolizumab 1200 mg intravenously every 3 weeks
Number of subjects: 837
Study 35798016 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily
Number of subjects: 837
Study 35798016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent cabozantinib 60 mg orally once daily
Number of subjects: 837
Study 34598050 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only social learning Cognitive Behavioral Therapy (SLCBT)
Number of subjects: 316
Study 34598050 — intervention group
Group type: COMPARATOR
Intervention: Education condition (control)
Number of subjects: 316
Study 32205810 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymph node dissection (LND) during radical cystectomy
Number of subjects: 0
Study 32205810 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical cystectomy with LND
Number of subjects: 0
Study 32205810 — intervention group
Group type: COMPARATOR
Intervention: Overall major complication, readmission and mortality rates
Number of subjects: 0
Study 33217147 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic per‐conditioning (RIC)
Number of subjects: 26
Study 33217147 — intervention group
Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 26
Study 34162490 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-to-mothership model
Number of subjects: 0
Study 34002707 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium
Number of subjects: 90
Study 34002707 — intervention group
Group type: COMPARATOR
Intervention: 500 mg mefenamic acid
Number of subjects: 90
Study 32946537 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 10143
Study 32946537 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra fees for hospital admission
Number of subjects: 10143
Study 35467436 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually delivered web-based legacy intervention
Number of subjects: 0
Study 35467436 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-animal interaction intervention for children with cancer
Number of subjects: 0
Study 32815892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze and postural stability (GPS) group
Number of subjects: 28
Study 32815892 — intervention group
Group type: COMPARATOR
Intervention: Strength and aerobic exercise (SAE) group
Number of subjects: 28
Study 36173726 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive envelope flap
Number of subjects: 60
Study 34495375 — intervention group
Group type: COMPARATOR
Intervention: isCGM
Number of subjects: 170
Study 34495375 — intervention group
Group type: COMPARATOR
Intervention: ABC
Number of subjects: 170
Study 34495375 — intervention group
Group type: COMPARATOR
Intervention: ABC+isCGM
Number of subjects: 170
Study 34495375 — intervention group
Group type: COMPARATOR
Intervention: isCGM alone
Number of subjects: 170
Study 32842971 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + FNC (Treatment as Usual + Informal Social Network Intervention)
Number of subjects: 105
Study 32842971 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 105
Study 35639621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 148
Study 35639621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 33455531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 254
Study 33455531 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 254
Study 33455531 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrepaired rupture (patients' ratings)
Number of subjects: 254